Pharmafile Logo
Pharmafocus logo
Advanced Search

Synergy Vision expands global presence to meet demand in the Asia-Pacific region

October 20, 2015
Medical Communications Asia-Pacific, Australia, Sydney, Synergy Vision, asia pacific, medical communcations

UK-based Synergy Vision opens a new office in Sydney, Australia, to meet the demands of their clients across the Asia-Pacific …

News
Press release

Recall after mislabelling of Medline Industries’ drugs

October 20, 2015
Manufacturing and Production US, acetaminophen, paracetamol, product recall

Medline Industries is voluntarily carrying out a nationwide recall of the painkiller acetaminophen, due to a labelling error on the …

News
China manufacturing

China’s Tianjin invests $300m in Ebola plant

October 20, 2015
Manufacturing and Production China, Ebola, Ebola vaccine, manufacturing, production, vaccines

China’s Tianjin CanSino Biotechnology, a developer of affordable vaccines, says that it will invest 2 billion Yuan (£203.3 million) in …

News
DNA

UK ‘is the best place in the world to do big data’, says AAR lead

October 20, 2015
Manufacturing and Production Accelerated Access Review, Big Data, Professor Sir John Bell

The UK is leading the world in developing new drugs from the analysis of big data, according to a leading …

News
nuevolution_logo

Nuevolution, Johnson & Johnson begin discovery collaboration

October 19, 2015
Manufacturing and Production, Research and Development Chemetics, Janssen Biotech, Nuevolution

Nuevolution and Janssen Biotech have entered into a collaboration which will use Nuevolution’s Chemetics drug discovery platform to facilitate discovery …

News
regeneron

Regeneron to invest $350 million, create 200 jobs in Ireland

October 19, 2015
Manufacturing and Production, Research and Development

US pharma company Regeneron has announced plans to invest $350 million into its production facility in Limerick, Ireland, creating 200 …

News
Allergan

2015’s top five mergers and acquisitions in a record-breaking year

October 19, 2015
Sales and Marketing Deals, acquisitions, mergers, pharma, takeovers

A new report from analysts MergerMarket reveals that mergers and acquisitions so far in 2015 have surpassed the same 2014 …

Feature
Flemming Ornskov

Shire’s dry eye treatment gets a no – for now

October 19, 2015
Sales and Marketing Complete Response Letter, FDA, Flemming Ornskov, Shire, dry eye disease, lifitegrast

Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …

News
BI building at night

FDA approves Boehringer’s Pradaxa reversal agent

October 19, 2015
Sales and Marketing Boehringer Ingelheim, FDA, Pradaxa, Praxbind, anticoagulant, idarucizumab

The FDA has approved Boehringer Ingelheim’s Praxbind, a reversal agent for its anticoagulant Pradaxa. The US regulator approved Praxbind (idarucizumab) …

News
Praluent

Sanofi and Regeneron heart drug Praluent available in UK

October 19, 2015
Sales and Marketing Regeneron, Sanofi, alicrocumab, high cholesterol, praluent

Sanofi and Regeneron’s next-generation cholesterol-lowering treatment Praluent is now available for adult patients with high cholesterol in the UK, following …

News
onglyza

FDA rejects AstraZeneca diabetes combination

October 16, 2015
Research and Development, Sales and Marketing AstraZeneca, FDA, NDA, dapagliflozin, saxagliptin

The FDA has declined to approve AstraZeneca’s New Drug Application (NDA) for the investigational fixed-dose combination of Onglyza and and …

News
pfizer_logo

Pfizer’s Xeljanz denied plaque psoriasis indication by FDA

October 16, 2015
Research and Development, Sales and Marketing FDA, Pfizer, Xeljanj, tofacitinib

The FDA has rejected the indication expansion of Pfizer’s Xeljanz (tofacitinib) for treatment of moderate to severe cases of plaque psoriasis. …

News
abbvies_humira_cost_the_most_to_market_in_the_us_last_month

Top 10 US pharma advertising spenders, September 2015

October 16, 2015
Medical Communications, Sales and Marketing

 As a new study from TV advertising metrics company iSpot reveals the top 40 pharma companies spent $231 million on TV …

Feature

NICE to recommend three new treatments for hep C

October 16, 2015
Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C

NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …

News
david_tweedale_and_ian_robinson

Ashfield UK makes two new business development appointments for its growing team

October 16, 2015
Medical Communications Ashfield UK

Ashfield has appointed David Tweedale and Ian Robinson as Business Development Managers to the UK Commercial and Clinical business, located …

Appointment
david_mustalish

The Prime Medical Group expands senior team in New York City

October 16, 2015
Medical Communications

The Prime Medical Group is pleased to announce several key appointments to its New York office as the company continues …

Appointment
texting mobile

Health apps now more popular than ever in the UK

October 16, 2015
Medical Communications apps, digital pharma, health technology, technology

The use of health apps has considerably increased over the past years, according to a new survey that has found …

News
NHS sign

NICE requests more evidence on Duchenne muscular dystrophy therapy

October 16, 2015
Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PCT Therapeutics, Translarna, ataluren

NICE has chosen not to recommend has PTC Therapeutics’ treatment Translarna for Duchenne muscular dystrophy (DMD), asking for further clarification …

News

The Prime Medical Group expands senior team in New York City

October 15, 2015
Medical Communications The Prime Medical Group

The Prime Medical Group is pleased to announce several key appointments to its New York office as the company continues …

News
Press release
Valeant logo

Valeant receives court writ over US drug pricing

October 15, 2015
Medical Communications, Sales and Marketing Drug pricing, Isuprel, Nitropress, US, Valeant, subpoena

Valeant Pharmaceuticals has disclosed that it has received two subpoenas in the US, demanding evidence concerning the pricing and distribution …

News
The Gateway to Local Adoption Series

Latest content

Sandoz opens biosimilar development centre in Slovenia

June 19, 2026

Codis announces three senior business development appointments

June 18, 2026

US laboratory approval supports launch of lung cancer blood test

June 17, 2026

Study to examine ways of improving diabetes care for younger adults

June 16, 2026

Phase 2 endometriosis trial reaches recruitment milestone

June 15, 2026